Eosinophilic inflammation in COPD: prevalence and clinical characteristics.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMID 25323230)

Published in Eur Respir J on October 16, 2014

Authors

Dave Singh1, Umme Kolsum2, Chris E Brightling3, Nicholas Locantore4, Alvar Agusti5, Ruth Tal-Singer6, ECLIPSE investigators

Author Affiliations

1: University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, Manchester, UK.
2: University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, Manchester, UK ukolsum@meu.org.uk.
3: Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
4: GlaxoSmithKline, Research and Development, Research Triangle Park, NC, USA.
5: Fundació Investigació Sanitària Illes Balears (FISIB), Centro de investigación biomedical en red de enfermedades respiratorias (CIBERES), Palma de Mallorca, Spain.
6: GlaxoSmithKline, Research and Development, King of Prussia, PA, USA.

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Articles citing this

Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.13

Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11

Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis (2016) 1.03

Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81

A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother (2015) 0.81

Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chron Obstruct Pulmon Dis (2015) 0.79

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med (2016) 0.79

Can we predict the prognosis of COPD with a routine blood test? Int J Chron Obstruct Pulmon Dis (2017) 0.77

Evidence of eosinophil extracellular trap cell death in COPD: does it represent the trigger that switches on the disease? Int J Chron Obstruct Pulmon Dis (2017) 0.75

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res (2017) 0.75

Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm. Int J Chron Obstruct Pulmon Dis (2017) 0.75

The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. Biomed Res Int (2016) 0.75

Asthma-COPD Overlap Syndrome: What We Know and What We Don't. Tuberc Respir Dis (Seoul) (2016) 0.75

Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis. BMJ Open (2016) 0.75

Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Nothing New Under the Sun. Immunol Allergy Clin North Am (2016) 0.75

Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Inhaled Steroids and Active Smoking Drive Chronic Obstructive Pulmonary Disease Symptoms and Biomarkers to a Greater Degree Than Airflow Limitation. Biomark Insights (2017) 0.75